TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival. The findings further validate TransCode’s TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system.
To view the full press release, visit https://ibn.fm/KTfMY
About TransCode Therapeutics
TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN